A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Clinical trial NCT05331326 · UNKNOWN
Trial details
- NCT number
- NCT05331326
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2023-12-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.